Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 2/2007

01.04.2007 | Review

Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies

verfasst von: Cecilia Grundtman, Vivianne Malmström, Ingrid E Lundberg

Erschienen in: Arthritis Research & Therapy | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Idiopathic inflammatory myopathies (IIMs), comprising polymyositis, dermatomyositis, and inclusion-body myositis, are characterized by inflammatory cell infiltrates in skeletal muscle tissue, muscle weakness, and muscle fatigue. The cellular infiltrates often consist of T lymphocytes and macrophages but also, in some cases, B lymphocytes. Emerging data have led to improved phenotypic characterization of the inflammatory cells, including their effector molecules, in skeletal muscle, peripheral blood, and other organs that are frequently involved, such as skin and lungs. In this review we summarize the latest findings concerning the role of T lymphocytes, B lymphocytes, dendritic cells, and other antigen-presenting cells in the pathophysiology of IIMs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Whitaker JN, Engel WK: Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972, 286: 333-338.CrossRefPubMed
2.
Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990, 27: 343-356. 10.1002/ana.410270402.CrossRefPubMed
3.
Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, et al: Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005, 52: 1824-1835. 10.1002/art.21103.CrossRefPubMed
4.
Grundtman C, Lundberg IE: Pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2006, 8: 188-195.CrossRefPubMed
5.
Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol.
6.
Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984, 16: 193-208. 10.1002/ana.410160206.CrossRefPubMed
7.
Emslie-Smith AM, Arahata K, Engel AG: Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989, 20: 224-231. 10.1016/0046-8177(89)90128-7.CrossRefPubMed
8.
Pedrol E, Grau JM, Casademont J, Cid MC, Masanes F, Fernandez-Sola J, Urbano-Marquez A: Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin Neuropathol. 1995, 14: 179-184.PubMed
9.
Engel AG, Arahata K, Emslie-Smith A: Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990, 68: 141-157.PubMed
10.
Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D: Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996, 97: 2905-2910.PubMedCentralCrossRefPubMed
11.
Orimo S, Koga R, Goto K, Nakamura K, Arai M, Tamaki M, Sugita H, Nonaka I, Arahata K: Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord. 1994, 4: 219-226. 10.1016/0960-8966(94)90022-1.CrossRefPubMed
12.
Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet. 2003, 362: 971-982. 10.1016/S0140-6736(03)14368-1.CrossRefPubMed
13.
Ikezoe K, Ohshima S, Osoegawa M, Tanaka M, Ogawa K, Nagata K, Kira JI: Expression of granulysin in polymyositis and inclusion-body myositis. J Neurol Neurosurg Psychiatry. 2006, 77: 1187-1190. 10.1136/jnnp.2005.081810.PubMedCentralCrossRefPubMed
14.
Hombach A, Kohler H, Rappl G, Abken H: Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol. 2006, 177: 5668-5675.CrossRefPubMed
15.
Benveniste O, Cherin P, Maisonobe T, Merat R, Chosidow O, Mouthon L, Guillevin L, Flahault A, Burland MC, Klatzmann D, et al: Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol. 2001, 167: 3521-3529.CrossRefPubMed
16.
Benveniste O, Herson S, Salomon B, Dimitri D, Trebeden-Negre H, Jean L, Bon-Durand V, Antonelli D, Klatzmann D, Boyer O: Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol. 2004, 56: 867-872. 10.1002/ana.20293.CrossRefPubMed
17.
Dimitri D, Benveniste O, Dubourg O, Maisonobe T, Eymard B, Amoura Z, Jean L, Tiev K, Piette JC, Klatzmann D, et al: Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain. 2006, 129: 986-995. 10.1093/brain/awl020.CrossRefPubMed
18.
Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G: Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004, 63: 297-301. 10.1136/ard.2003.006122.PubMedCentralCrossRefPubMed
19.
Yamadori I, Fujita J, Kajitani H, Bandoh S, Tokuda M, Ohtsuki Y, Yoshinouchi T, Okahara M, Yamaji Y, Tanimoto Y, et al: Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int. 2001, 21: 89-93. 10.1007/s00296-001-0146-y.CrossRefPubMed
20.
Sauty A, Rochat T, Schoch OD, Hamacher J, Kurt AM, Dayer JM, Nicod LP: Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J. 1997, 10: 2907-2912. 10.1183/09031936.97.10122907.CrossRefPubMed
21.
Kourakata H, Takada T, Suzuki E, Enomoto K, Saito I, Taguchi Y, Tsukada H, Nakano M, Arakawa M: Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia. Respirology. 1999, 4: 223-228. 10.1046/j.1440-1843.1999.00179.x.CrossRefPubMed
22.
Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, Kuriyama T, Sueishi M, Saito Y, Iwamoto I: Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002, 129: 541-548. 10.1046/j.1365-2249.2002.01933.x.PubMedCentralCrossRefPubMed
23.
Englund PWJ, Fathi M, Rasmussen E, Grunewald J, Tornling G, Lundberg IE: Restricted TCR BV gene usage in lungs and muscle tissue of patients with idiopathic inflammatory myopathies. Arthrithis Rheum. 2007, 56: 372-383. 10.1002/art.22293.CrossRef
24.
Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Hartlein M, Kron M, Yang D, et al: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002, 196: 781-791. 10.1084/jem.20020186.PubMedCentralCrossRefPubMed
25.
Chino Y, Murata H, Goto D, Matsumoto I, Tsutsumi A, Sakamoto T, Ohtsuka M, Sekisawa K, Ito S, Sumida T: T cell receptor BV gene repertoire of lymphocytes in bronchoalveolar lavage fluid of polymyositis/dermatomyositis patients with interstitial pneumonitis. Int J Mol Med. 2006, 17: 101-109.PubMed
26.
Hohlfeld R, Engel AG: Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol. 1991, 29: 498-507. 10.1002/ana.410290509.CrossRefPubMed
27.
O'Donovan MR, Jones DR, Robins RA, Li KF, Shim HK, Zheng Z, Arlett CF, Capulas E, Cole J: Co-cultivation of CD4+ and CD8+ human T-cells leads to the appearance of CD4 cells expressing CD8 through de novo synthesis of the CD8 α-subunit. Hum Immunol. 1999, 60: 1018-1027. 10.1016/S0198-8859(99)00098-1.CrossRefPubMed
28.
Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, Nemcova D, Charvat F: Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000, 29: 95-102. 10.1080/030097400750001897.CrossRefPubMed
29.
Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, Miyasaka N: Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005, 23: 707-710.PubMed
30.
Mitsui T, Kuroda Y, Kunishige M, Matsumoto T: Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005, 44: 1197-1199. 10.2169/internalmedicine.44.1197.CrossRefPubMed
31.
Lampropoulos CE, DP DC: Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis. 2005, 64: 1376-1377. 10.1136/ard.2004.032714.PubMedCentralCrossRefPubMed
32.
Stashenko P, Nadler LM, Hardy R, Schlossman SF: Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA. 1981, 78: 3848-3852. 10.1073/pnas.78.6.3848.PubMedCentralCrossRefPubMed
33.
Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984, 63: 1424-1433.PubMed
34.
Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O'Connor KC, Amato AA: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005, 65: 1782-1787. 10.1212/01.wnl.0000187124.92826.20.CrossRefPubMed
35.
Bradshaw EM, Orihuela A, McArdel SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O'Connor KC: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol. 2007, 178: 547-556.CrossRefPubMed
36.
Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis. 2001, 60: 1137-1140. 10.1136/ard.60.12.1137.PubMedCentralCrossRefPubMed
37.
Cambridge G, Faith A, Saunders C, Dubowitz V: A comparative study of in vitro proliferative responses to mitogens and immunoglobulin production in patients with inflammatory muscle disease. Clin Exp Rheumatol. 1989, 7: 27-33.PubMed
38.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991, 70: 360-374.CrossRef
39.
Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, et al: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001, 60: 116-123. 10.1136/ard.60.2.116.PubMedCentralCrossRefPubMed
40.
Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54: 3682-3689. 10.1002/art.22164.CrossRefPubMed
41.
Dalakas MC, Illa I, Gallardo E, Juarez C: Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997, 41: 100-104. 10.1002/ana.410410116.CrossRefPubMed
42.
Page G, Sattler A, Kersten S, Thiel A, Radbruch A, Miossec P: Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol. 2004, 164: 409-417.PubMedCentralCrossRefPubMed
43.
Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005, 52: 601-607. 10.1002/art.20849.CrossRefPubMed
44.
Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006, 33: 1021-1026.PubMed
45.
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001, 294: 1540-1543. 10.1126/science.1064890.CrossRefPubMed
46.
Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003, 19: 225-234. 10.1016/S1074-7613(03)00208-5.CrossRefPubMed
47.
Page G, Chevrel G, Miossec P: Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum. 2004, 50: 199-208. 10.1002/art.11428.CrossRefPubMed
48.
Greenberg SA, Pinkus GS, Amato AA, Pinkus JL: Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007, 35: 17-23. 10.1002/mus.20649.CrossRefPubMed
49.
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, et al: Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed
50.
Oppenheim JJ, Yang D, Biragyn A, Howard OM, Plotz P: Chemokine receptors on dendritic cells promote autoimmune reactions. Arthritis Res. 2002, 4 (Suppl 3): S183-188. 10.1186/ar574.PubMedCentralCrossRefPubMed
51.
Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991, 9: 271-296. 10.1146/annurev.iy.09.040191.001415.CrossRefPubMed
52.
Curnow SJ, Willcox N, Vincent A: Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNγ secretion and cytotoxicity. J Neuroimmunol. 1998, 86: 53-62. 10.1016/S0165-5728(98)00013-7.CrossRefPubMed
53.
Murata K, Dalakas MC: Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol. 1999, 155: 453-460.PubMedCentralCrossRefPubMed
54.
Murata KY, Sugie K, Takamure M, Ueno S: Expression of the costimulatory molecule BB-1 and its receptors in patients with scleroderma-polymyositis overlap syndrome. J Neurol Sci. 2002, 205: 65-70. 10.1016/S0022-510X(02)00309-X.CrossRefPubMed
55.
Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R: Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol. 1998, 161: 5943-5951.PubMed
56.
Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995, 63: 9-16. 10.1016/0165-5728(95)00122-0.CrossRefPubMed
57.
Dalakas MC: Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol. 1998, 55: 1509-1512. 10.1001/archneur.55.12.1509.CrossRefPubMed
58.
Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997, 40: 865-874. 10.1002/art.1780400514.CrossRefPubMed
59.
Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R, Weller M: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain. 2003, 126: 1026-1035. 10.1093/brain/awg017.CrossRefPubMed
60.
Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N, et al: Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol. 2000, 164: 6593-6600.CrossRefPubMed
61.
Schmidt J, Rakocevic G, Raju R, Dalakas MC: Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain. 2004, 127: 1182-1190. 10.1093/brain/awh148.CrossRefPubMed
62.
Hengstman GJ, van Engelen BG: Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ. 2004, 329: 1464-1467. 10.1136/bmj.329.7480.1464.PubMedCentralCrossRefPubMed
Metadaten
Titel
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies
verfasst von
Cecilia Grundtman
Vivianne Malmström
Ingrid E Lundberg
Publikationsdatum
01.04.2007
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 2/2007
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2139

Weitere Artikel der Ausgabe 2/2007

Arthritis Research & Therapy 2/2007 Zur Ausgabe

Research article

Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter

Review

Developments in the synovial biology field 2006

Review

Cells of the synovium in rheumatoid arthritis. B cells

Commentary

T cells and post menopausal osteoporosis in murine models

Research article

Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis

Commentary

Impact of cytokines and T lymphocytes upon osteoclast differentiation and function

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise